---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-462199"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2026-11-16T13:15:21+00:00"
generated_at: "2026-11-16T13:20:50.238276+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# CG Oncology PIVOT-006 Phase 3 wins: 68% recurrence risk cut (HR 0.32) in NMIBC

## Summary
- Cretostimogene cut recurrence risk 68% vs control in adjuvant intermediate-risk/high-grade Ta ≤3cm NMIBC; HR 0.32 (95% CI 0.23-0.45; p<0.0001), median follow-up 17 months.
- No Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations; safety consistent with prior studies.
- Initial BLA in BCG-unresponsive NMIBC broadened per FDA feedback to include high-grade papillary-only disease plus CIS; completion now expected by end of March 2027.
- Second BLA in intermediate-risk and high-grade Ta NMIBC planned for Q2 2027; ~50,000 US patients in this population have no FDA-approved adjuvant option.
- Topline results to be presented as a late-breaking podium at the Society of Urologic Oncology Annual Meeting on December 2, 2026.

## SEC filing metadata
- accession: 0001193125-26-462199
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2026-11-16T13:15:21+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312526462199/0001193125-26-462199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312526462199/ck0001991792-20261116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-462199
- JSON: https://secwatch.observer/filing/0001193125-26-462199.json
- Plain text: https://secwatch.observer/filing/0001193125-26-462199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
